{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:38:56Z","timestamp":1793777936401,"version":"4.6.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.autrev.2025.103865","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:17:56Z","timestamp":1751887076000},"page":"103865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy"],"prefix":"10.1016","volume":"24","author":[{"given":"Angeliki Zoi","family":"Lignou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos D.","family":"Vassilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0005","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-022-05136-x","article-title":"The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era","volume":"42","author":"Evangelatos","year":"2022","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"49","author":"Boleto","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0020","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103865_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0030","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103865_bb0035","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1093\/rheumatology\/keaa880","article-title":"Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination","volume":"60","author":"Haberman","year":"2021","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.autrev.2025.103865_bb0040","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/rheumatology\/key199","article-title":"Combined inhibition of tumour necrosis factor-alpha and interleukin-12\/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?","volume":"57","author":"De Marco","year":"2018","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0050","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/apt.15891","article-title":"Letter: combination of biologics in inflammatory bowel diseases","volume":"52","author":"Fumery","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.autrev.2025.103865_bb0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0060","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2021-221812","article-title":"Effectiveness and safety of combined biological therapy in patients with refractory multidomain spondyloarthritis","volume":"81","author":"Valero","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2020.02.017","article-title":"Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center","volume":"19","author":"Kwapisz","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2015","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.autrev.2025.103865_bb0080","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000243","article-title":"Safety of dual biological therapy in Crohn\u2019s disease: a case series of vedolizumab in combination with other biologics","volume":"5","author":"Mao","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103865_bb0090","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/00365521.2022.2045350","article-title":"Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study","volume":"57","author":"Eronen","year":"2022","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dld.2022.07.012","article-title":"Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study","volume":"55","author":"Guillo","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"15","author":"Privitera","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0105","first-page":"394","article-title":"Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report","volume":"18","author":"Rathod","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.13752","article-title":"Novel combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis in a medically complex patient","volume":"63","author":"Hanna","year":"2022","journal-title":"Australas J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103865_bb0115","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1093\/ibd\/izaa275","article-title":"SARS-CoV-2 infection and dual-biologic therapy for Crohn\u2019s disease","volume":"26","author":"Dimopoulos","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.autrev.2025.103865_bb0120","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001203","article-title":"Dual biologic therapy for refractory Crohn\u2019s disease with perforation in a patient declining surgical intervention","volume":"10","author":"Le","year":"2023","journal-title":"ACG Case Rep J"},{"issue":"8","key":"10.1016\/j.autrev.2025.103865_bb0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0130","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1097\/RHU.0000000000001767","article-title":"Combination therapy with tofacitinib and IL-12\/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis. JCR","volume":"28","author":"Shurey","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103865_bb0135","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/ard-2024-225800","article-title":"Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series","volume":"83","author":"Hren","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ibd\/izab176","article-title":"Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn\u2019s disease","volume":"28","author":"Lee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","article-title":"A case series on patients on tofacitinib in combination with a biologic","volume":"24","author":"Barroso","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0155","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cgh.2020.07.046","article-title":"Tofacitinib is safe and effective when used in combination with infliximab for the management of refractory ulcerative colitis","volume":"19","author":"Gilmore","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2025.103865_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074329","article-title":"Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0165","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/imj.16120","article-title":"Combination non tumour necrosis factor biologic and small-molecule therapy in a patient with ankylosing spondylitis and Crohn disease","volume":"53","author":"Li","year":"2023","journal-title":"Intern Med J"},{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0170","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis","volume":"6","author":"Wang","year":"2019","journal-title":"ACG Case Rep J"},{"issue":"11","key":"10.1016\/j.autrev.2025.103865_bb0175","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1093\/ibd\/izaa158","article-title":"Treatment of ulcerative colitis and seronegative inflammatory spondyloarthritis with vedolizumab and tofacitinib","volume":"26","author":"Lee","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ejhpharm-2020-002437","article-title":"A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib","volume":"28","author":"Taberner Bonastre","year":"2021","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0185","article-title":"Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease","volume":"3","author":"Llano","year":"2021","journal-title":"Crohns Colitis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0190","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/diseases10040102","article-title":"Effectiveness of dual biologic or small molecule therapy for achieving endoscopic remission in refractory inflammatory bowel disease","volume":"10","author":"Abdullah","year":"2022","journal-title":"Diseases"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2016-000127","article-title":"Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis","volume":"4","author":"Bethge","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjx142","article-title":"Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy","volume":"12","author":"Roblin","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.autrev.2025.103865_bb0210","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103865_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212819","article-title":"Simultaneous inhibition of \u03b14\/\u03b27 integrin and tumour necrosis factor-\u03b1 in concomitant spondyloarthritis and inflammatory bowel disease","volume":"77","author":"Richard","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0220","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining anti-TNF-\u03b1 and vedolizumab in the treatment of inflammatory bowel disease: a case series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0225","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/apt.16271","article-title":"Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy","volume":"53","author":"Privitera","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/medicina60030360","article-title":"Tofacitinib and baricitinib in type 2 diabetic patients with rheumatoid arthritis","volume":"60","author":"Martinez-Molina","year":"2024","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.autrev.2025.103865_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5264216","article-title":"Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn\u2019s disease","volume":"2017","author":"Liu","year":"2017","journal-title":"Case Rep Med"},{"key":"10.1016\/j.autrev.2025.103865_bb0240","doi-asserted-by":"crossref","DOI":"10.17235\/reed.2022.9194\/2022","article-title":"Use of teduglutide for short bowel syndrome and Crohn\u2019s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy","author":"Mart\u00ed Romero","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"issue":"7","key":"10.1016\/j.autrev.2025.103865_bb0245","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/ibd\/izaa092","article-title":"Double biologic therapy for refractory stricturing Crohn\u2019s disease: a successful case of deep remission with ustekinumab and vedolizumab","volume":"26","author":"Elmoursi","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.autrev.2025.103865_bb0250","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/MEG.0000000000001919","article-title":"Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab","volume":"32","author":"Biscaglia","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103865_bb0255","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/MIB.0000000000001232","article-title":"Efficacy of combination vedolizumab and ustekinumab for refractory Crohn\u2019s disease","volume":"23","author":"Huff-Hardy","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0260","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1203475416631328","article-title":"Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0265","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1573397115666181130094455","article-title":"Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis","volume":"15","author":"Metyas","year":"2019","journal-title":"Curr Rheumatol Rev"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0270","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1346-8138.15193","article-title":"Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue","volume":"47","author":"Takamura","year":"2020","journal-title":"J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103865_bb0275","doi-asserted-by":"crossref","DOI":"10.1111\/ced.14000","article-title":"Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis","volume":"44","author":"Sacchelli","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0280","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/2475530318788934","article-title":"Apremilast in combination with an interleukin 17A inhibitor in the treatment of recalcitrant palmoplantar psoriasis","volume":"3","author":"Alomran","year":"2018","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0285","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/ijd.IJD_548_18","article-title":"Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic","volume":"64","author":"De","year":"2019","journal-title":"Indian J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0290","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/jocd.14367","article-title":"Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis","volume":"21","author":"Zimmer","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5152\/eurjrheum.2018.17188","article-title":"Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: a novel approach","volume":"6","author":"Nisar","year":"2019","journal-title":"Eur J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0300","first-page":"648","article-title":"Apremilast and secukinumab combined therapy in a patient with recalcitrant plaque psoriasis","volume":"15","author":"Rothstein","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0305","article-title":"Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis","volume":"21","author":"Danesh","year":"2015","journal-title":"Dermatol Online J"},{"issue":"03","key":"10.1016\/j.autrev.2025.103865_bb0310","article-title":"Treatment of palmoplantar pustulosis with the combination of ustekinumab and apremilast: a case report","volume":"02","author":"Mayba","year":"2016","journal-title":"Arch Case Rep Clin Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0315","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/247553031700200203","article-title":"Secukinumab and apremilast combination therapy for recalcitrant psoriasis","volume":"2","author":"Hadi","year":"2017","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0320","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40291-018-0354-8","article-title":"Treating a multidrug-resistant psoriatic HLA-C*18:01 allele carrier with combination ustekinumab apremilast therapy","volume":"22","author":"Galluzzo","year":"2018","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0325","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14464","article-title":"Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID -19 pandemic","volume":"33","author":"Armesto","year":"2020","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0330","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0335","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2025.103865_bb0340","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/ken491","article-title":"Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis","volume":"48","author":"Blank","year":"2009","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0345","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3899\/jrheum.090160","article-title":"Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-\u03b1-blocking agents","volume":"36","author":"Koumakis","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0350","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1874312900903010009","article-title":"Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after TNF failure: case report","volume":"3","author":"Tony","year":"2009","journal-title":"Open Rheumatol J"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0355","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.120924","article-title":"Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study","volume":"40","author":"Rigby","year":"2013","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0360","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5152\/EuJRheum.2022.21180","article-title":"Dual biologic therapy in patients with familial Mediterranean fever and spondyloarthritis: case-based review","volume":"10","author":"Yildirim","year":"2023","journal-title":"Eur J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0370","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1136\/annrheumdis-2022-222415","article-title":"Sequential interleukin-17\/interleukin-23 inhibition in treatment-refractory psoriatic arthritis","volume":"81","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103865_bb0375","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kel211","article-title":"Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy","volume":"45","author":"Sheehy","year":"2006","journal-title":"Rheumatology"},{"issue":"9894","key":"10.1016\/j.autrev.2025.103865_bb0380","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2025.103865_bb0385","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103865_bb0390","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.cgh.2020.10.025","article-title":"Real-world effectiveness and safety of tofacitinib in Crohn\u2019s disease and IBD-U: a multicenter study from the TROPIC consortium","volume":"19","author":"Fenster","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0395","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103865_bb0400","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New Engl J Med"},{"issue":"20","key":"10.1016\/j.autrev.2025.103865_bb0405","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0410","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2025.103865_bb0415","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.autrev.2025.103865_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233781","article-title":"Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis","volume":"15","author":"Burisch","year":"2020","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2025.103865_bb0425","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14740338.2021.1960981","article-title":"Gastroenterological safety of IL-17 inhibitors: a systematic literature review","volume":"21","author":"Caron","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.autrev.2025.103865_bb0430","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103865_bb0435","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2025.103865_bb0440","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","article-title":"Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry","volume":"63","author":"Vassilakis","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103865_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The assessment of spondyloarthritis international society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103865_bb0450","series-title":"A study of combination treatment with MabThera (rituximab) and RoActemra (tocilizumab) versus RoActemra in patients with rheumatoid arthritis with an incomplete response to methotrexate","author":"Hoffmann-La Roche (Responsible Party)","year":"2025"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:12:29Z","timestamp":1764648749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":90,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1568997225001259"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103865","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103865"}}